Trilantic Capital Partners Europe, a private equity firm focused on mid-market transactions in Europe, has completed the acquisition of a 90% shareholding in Doppel Farmaceutici after obtaining antitrust approvals.
Doppel is an operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a contract development and manufacturing organization (CDMO). Financial details of the investment have not been disclosed.
Paolo Lanfranchi has moved from his previous role as managing director to become chairman of Doppel. Giuseppe Cassisi, who has 30 years of experience in the pharmaceuticals and CDMO sector, has become the company’s chief executive officer.
Trilantic Europe and Doppel’s management team have put in place a strategy focused on expanding Doppel both organically and as a platform to acquire other players in the CDMO sector. The strategy also includes plans to increase Doppel’s presence in international markets, such as the U.S. and the Far East, strengthening the company’s offer in R&D, strategic growth through the acquisition of niche capabilities such as injectable biotechnology medicines, and the development of greenfield projects.
Doppel, which was founded in 1994, has contracts with blue-chip Italian and international clients. The company has 460 employees and operates from two production plants in northern Italy.